Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-09-01
1997-09-23
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514261, 544 61, 544118, 544277, 549336, C07D47334, C07D31772, A61K 3152, A61K 31535
Patent
active
056705018
ABSTRACT:
Optically active or racemic compounds represented by the formula ##STR1## where R.sub.1 is C.sub.1 to C.sub.4 straight chain or branched alkyl; R.sub.2 is selected from the group consisting of H, --OR.sub.1, --SR.sub.1, --NH(R.sub.1), --N(R.sub.4)(R.sub.5), aminocarbonyl, halogen, and --CN, where R.sub.4 and R.sub.5 are independently C.sub.1 to C.sub.6 straight chain or branched alkyl, or taken together form a 3- to 7-membered heterocycloalkyl substituent, such heteroatom selected from the group consisting of oxygen, nitrogen and sulfur, optionally including an additional heteroatom which is selected from the group consisting of nitrogen, oxygen, and sulfur; R.sub.3 is cyclopentyl or: ##STR2## where R' and R" are independently H, .dbd.O, --OH, or --NH.sub.2, with the proviso that R' and R" can be taken together form the following structure as R.sub.3 : ##STR3## where R'" is --OH or --NH.sub.2 ; and with the further proviso that when R.sub.3 is cyclopentyl or norbornyl, then R.sub.2 cannot be H or halogen; and pharmaceutically-acceptable salts thereof. These compounds are useful as diuretics, renal protectives against acute or chronic renal failure, as well as agents to facilitate recovery from coma, to improve the therapeutic outcome resulting from defibrillation or cardiopulmonary resuscitation by preventing post-resuscitation bradycardia, bradyarrhythmia and cardioplegia, to restore cardiac function following a cardioplegic procedure, and to treat or prevent intermittent claudication.
REFERENCES:
patent: 3929763 (1975-12-01), Fauland et al.
patent: 3989833 (1976-11-01), Jonas et al.
patent: 4364922 (1982-12-01), Berne et al.
patent: 4612315 (1986-09-01), Jacobson et al.
patent: 4714697 (1987-12-01), Trivedi
patent: 4751292 (1988-06-01), Fox
patent: 4853386 (1989-08-01), Friebe et al.
patent: 4980379 (1990-12-01), Belardinelli et al.
patent: 5066655 (1991-11-01), Olsson
patent: 5117830 (1992-06-01), McAfee
Bertolet et al., "Attenuation of Adenosine-Induced Chest Pain with N-0861 (N.sup.6 -Endonorbornan-2-yl-9-methyladenine), A Selective A.sub.1 Adenosine Receptor Antagonist," Presented at the American College of Cardiology 43rd Annual Scientific Session, (Mar. 1994).
Carstens and Goldner, "6,9-Disubstituted purine derivatives," Chem. Abstracts 56(9):Abstract No. 10167i-10168d (1962).
Daly et al., "Structure-Activity Relationship for N.sup.6 -Substituted Adenosines at A Brain A.sub.1 -Adenosine Receptor with A Comparison to an A.sub.2 -Adenosine Receptor Regulating Coronary Blood Flow," Biochem. Pharmacol. 35(15):2467-2481 (1986).
Jacobson et al., "Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential," J. Med. Chem. 35(3):407-422 (1992).
Martin et al., "(+)-N.sup.6 -Endonorbornan-2-yl-9-Methyladenine (N-0861) and its Enantiomers: Selective Antagonists of A.sub.1 -Adenosine Receptors in Guinea Pig Isolated Atria," J. Pharmacol. Exp. Ther. 265(1):201-206 (1993).
Rose et al., "Safety, Tolerability, Renal Effects and Pharmacokinetics in Man of Single Doses of FK453, A Novel Adenosine A.sub.1 Receptor Antagonist," Presented at the British Pharmacological Society Meeting, Abstract No. P149 (1991).
Shimada et al., "8-(Dicyclopropylmethyl)-1,3-dipropylxanthine: A Potent and Selective Adenosine A.sub.1 Antagonist with Renal Protective and Diuretic Activities," J. Med. Chem. 34(1):466-469 (1991).
Stein and Somani, "Cardiovascular Effects Of Nucleoside Analogs," Annals NY Acad. Sci. 255:380-389 (1975).
Stiles, G.L., "Adenosine receptors: structure, function and regulation, " TIPS Reviews:486-490 (Dec. 1986).
Terai et al., "The renal effects of FR-113453, a potent non-xanthine adenosine antagonist," XIth Intl. Cong. of Pharmacol., Amsterdam, The Netherlands, Abstract No. P.tu.435 (Jul. 2-6, 1990).
Thompson et al., "N.sup.6, 9-Disubstituted Adenines: Potent, Selective Antagonists at the A.sub.1 Adenosine Receptor," J. Med. Chem. 34:2877-2882 (1991).
Ukena, D., "Definition of subclasses of adenosine receptors associated with adenylate cyclase: interaction of adenosine analogs with inhibitory A.sub.1 receptors and stimulatory A.sub.2 receptors," Can. J. Physiol. Pharmacol. 65:365-376 (1987).
Ukena et al., "N.sup.6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists," FEBS Lett. 215(2):203-208 (1987).
Williams, M., "Adenosine Antagonists," Med. Res. Rev. 9(2):219-243 (1989).
Barrett, Drug. Devel. Res. 32, 196 (1994).
Ukena, FEBS 209, 122 (1986).
Wesley, Jr, Cardiovascular Res 27, 129 (1993).
Genetic Engineering News, Nov. 1, 1994, p. 32 "Gensias Protara Fails . . . ".
Jacobsen, Proc. Natl. Acad. Sci USA 83, 4089 (1986).
Cusack Noel J.
Peck James V.
Uwaydah Ibrahim M.
Wysocki Ronald J.
Berch Mark L.
Discovery Therapeutics Inc.
LandOfFree
N-substituted 9-alkyladenines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-substituted 9-alkyladenines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-substituted 9-alkyladenines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1938724